Copyright 2006-2010 Abiant, Inc.
Imaging Experience
Full Clinical Studies
    
 
Therapeutic Class
Compounds
Objectives
  Mood disorders
 Buspirone
 Acute, Steady state, Washout profile
    Paroxetine and other SSRI, SNRI
compounds
 Comparative effects upon regional glucose
metabolism
    CRF1 targeted compound
 Central effect, dose response
    NK1 targeted compounds
 Dose response, therapeutic and side effect
profiles; comparison of two pipeline
compounds
    Novel receptor targeted cmpd
 Central effect at multiple time points; dose
response
  Sedative anxiolytic
 Lorazepam
 Central effect; comparison of active and
neutral tasks during uptake
  Sedative-hypnotic
 Zolpidem
 Comparison to a pipeline compound
  Epilepsy / Pain
 Gabapentin
 Comparison to a pipeline compound
  Other GABA modulator
 Voltage gated Ca++ channel
targeted cmpd
 Central effect; comparison to known drugs
  Attention Deficit Disorder
 Methylphenidate
 Central effect; effect of task during FDG
uptake
  Schizophrenia
 Cmpd targeted at novel receptor
 Central effect, dose response
  Other
 Cmpd targeted at novel receptor
 Biodistribution
    Cmpd targeted at novel receptor
 Central effect, dose response
  Non-CNS drugs
 Tolteradine
Selective muscarinic targeted cmpd
 Comparison of side effect profiles
We have successfully conducted imaging studies on
a comprehensive array of CNS and non-CNS
compounds including listed below.  In particular, we
have demonstrated a unique ability to obtain data on
novel compounds for which a receptor specific ligand
reference compound data to which novel drug effects
can be compared.

Below are examples of clinical studies and data
analyses we have conducted.
Abiant, Inc.  480 West Center Street, Suite 202, Grayslake, Illinois  60030
Full Preclinical Studies
 
 
Species
PET Tracer
Objectives
  Rhesus macaque
 C11-labeled novel compound
 Biodistribution
  Rhesus macaque
 DASB
 DASB uptake measurement
  Rhesus macaque
 FDG
 Effect of ketamine upon glucose metabolism
measurement
Comparison of the glucose metabolic effects
of two acute doses of a novel compound
targeting the NK1 receptor system.
Data QC and Analysis
 
 
 
Study
Compound or Disease State
Analyses
  All clinical and preclinical
studies listed under Full Studies
 Multiple
 Data quality control and outlier identification,
region of interest analysis, SPM, Multivariate
Analysis
  Multi-site receptor occupancy
studies
 Multiple
 Data quality control, receptor occupancy
calculation, reporting, archival
  ADNI
 Normal, MCI, AD, converters
at baseline  (> 300 subjects)
 Region of interest, SPM, Multivariate analyses
of cross-class comparisons, correlations to
other biomarkers
  ADNI
 Normal, MCI, AD longitudinal
progression:  FDG PET, 11C-PIB
 Region of interest, SPM, Multivariate analysis
  ADNI
 MCI sub-classification according to
clinical progression (> 400 scans)
 Region of interest, Multivariate analysis,
correlations to cognitive data, other
biomarkers
  Multi-site
 Normal, AD, Frontotemporal dementia
 correlations to cognitive data and other
biomarkers
  Preclinical data
 Novel receptor targeted compound
 Translation of 2D data to 3D volumetric data
for SPM analyses
Drug Evaluation...